Back to Directory Collin Delgado Email delgado@frontierscience.org Institution Frontier Science Foundation Request an Update Affiliated Studies IMPAACT 2052: Safety and pharmacokinetics of an AAV-Vectored broadly neutralizing antibody in infants living with HIV DAIDS Number 39268 Research Area Cure and Immunotherapy Study Status In Development IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Open to Accrual IMPAACT 2050: CREATE DAIDS Number 39208 Research Area Treatment Study Status Pending
IMPAACT 2052: Safety and pharmacokinetics of an AAV-Vectored broadly neutralizing antibody in infants living with HIV DAIDS Number 39268 Research Area Cure and Immunotherapy Study Status In Development
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Open to Accrual
